nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

21.03.2019 | Original Article – Cancer Research

Heart myxoma develops oncogenic and metastatic phenotype

verfasst von: Silvia Cecilia Pacheco-Velázquez, Juan Carlos Gallardo-Pérez, Daniel Díaz, Alhelí Adán-Ladrón de Guevara, Diana Xochiquetzal Robledo-Cadena, Emma Saavedra, Luz Ruiz-Godoy, Luis Roberto Jimenez-Hernández, Jesús Vargas-Barrón, José Luis Aguilar-Ponce, Sara Rodríguez-Enríquez

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Heart myxomas have been frequently considered as benign lesions associated with Carney’s complex. However, after surgical removal, myxomas re-emerge causing dysfunctional heart.

Methods

To identify whether cardiac myxomas may develop a metastatic phenotype as occurs in malignant cancers, a profile of several proteins involved in malignancy such as oncogenes (c-MYC, K-RAS and H-RAS), cancer-associated metabolic transcriptional factors (HIF-1α, p53 and PPAR-γ) and epithelial–mesenchymal transition proteins (fibronectin, vimentin, β-catenin, SNAIL and MMP-9) were evaluated in seven samples from a cohort of patients with atrial and ventricular myxomas. The analysis was also performed in: (1) cardiac tissue surrounding the area where myxoma was removed; (2) non-cancer heart tissue (NCHT); and (3) malignant triple negative breast cancer biopsies for comparative purposes.

Results

Statistical analysis applying univariate (Kruskal–Wallis and Dunn’s tests) and multivariate analyses (PCA, principal component analysis) revealed that heart myxomas (7–15 times) and myxoma surrounding tissue (22–99 times) vs. NCHT showed high content of c-MYC, p53, vimentin, and HIF-1α, indicating that both myxoma and its surrounding area express oncogenes and malignancy-related proteins as occurs in triple negative breast cancer.

Conclusions

Based on ROC (receiver operating characteristics) statistical analysis, c-MYC, HIF-1α, p53, and vimentin may be considered potential biomarkers for malignancy detection in myxoma.

Nur mit Berechtigung zugänglich

Abba MC, Lacunza E, Butti M, Aldaz CM (2010) Breast cancer biomarker discovery in the functional genomic age: a systematic review of 42 gene expression signatures. Biomark Insights 5:103–118. https://doi.org/10.4137/BMI.S5740 CrossRefPubMedPubMedCentral

Aguirre-Benítez EL, Porras MG, Parra L, González-Ríos J, Garduño-Torres DF, Albores-García D, Avendaño A, Ávila-Rodríguez MA, Melo AI, Jiménez-Estrada I, Mendoza-Garrido ME, Toriz C, Diaz D, Ibarra-Coronado E, Mendoza-Ángeles K, Hernández-Falcón J (2017) Disruption of behavior and brain metabolism in artificially reared rats. Dev Neurobiol 77(12):1413–1429. https://doi.org/10.1002/dneu.22548 CrossRefPubMed

Altundag MB, Ertas G, Ucer AR, Durmus S, Abanuz H, Calikoğlu T, Ozbagi K, Demirkasimoglu A, Kaya B, Bakkal BH, Altundag K (2005) Brain metastasis of cardiac myxoma: case report and review of the literature. J Neurooncol 75(2):181–184. https://doi.org/10.1007/s11060-005-1859-7 CrossRefPubMed

Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2):S73–S81. https://doi.org/10.3816/CBC.2009.s.008 CrossRefPubMedPubMedCentral

Barh D, Kumar A, Chatterjee S, Liloglou T (2009) Molecular features, markers, drug targets, and prospective targeted therapeutics in cardiac myxoma. Curr Cancer Drug Targets 9(6):705–716. https://doi.org/10.2174/156800909789271549 CrossRefPubMed

Bartlett JEII, Kotrlik JW, Higginsm CC (2001) Organizational research: determining appropriate sample size in survey. Off Syst Res J 19(1):43–50. https://doi.org/10.5306/wjco.v6.i6.252 CrossRef

Becker RP, Ramírez MA, Zalaquett SR, Moran VS, Irarrázaval LI MJ, Arretz VC, Córdova AS, Arnaiz GP (2008) Cardiac myxoma: clinical characterization, diagnostic methods and late surgical results. Rev Med Chil 136(3):287–295CrossRef

Biddlestone J, Bandarra D, Rocha S (2015) The role of hypoxia in inflammatory disease (review). Int J Mol Med 35(4):859–869. https://doi.org/10.3892/ijmm.2015.2079 CrossRefPubMedPubMedCentral

Björklund M, Koivunen E (2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755(1):37–69. https://doi.org/10.1016/j.bbcan.2005.03.001 CrossRefPubMed

Blackmon SH, Kassis ES, Ge Y, Goldfarb R, Reardon M (2010) Left atrial myxoma embolus to the renal artery: should a nephrectomy be advised? Ann Thorac Surg 90(1):289–292. https://doi.org/10.1016/j.athoracsur.2009.11.059 CrossRefPubMed

Burke A, Jeudy J, Virmani R (2007) Textbook of cardiovascular medicine. Lippincott Williams and Wilkins, Philadelphia

Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, ESMO Guidelines Working Group (2012) Locally recurrent or metastatic breast cancer: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii11–9. https://doi.org/10.1093/annonc/mds232 CrossRefPubMed

Carney JA (1985) Differences between non-familial and familial cardiac myxoma. Am J Surg Pathol 9(1):53–55. https://doi.org/10.1097/00000478-198501000-00009 CrossRefPubMed

Chambers JM, Cleveland WS, Kleiner B, Tukey PA (1983) Graphical methods for data analysis. Chapman and Hall/Cole Publishing Company, London

Chen Y, Olopade OI (2008) MYC in breast tumor progression. Expert Rev Anticancer Ther 8(10):1689–1698. https://doi.org/10.1586/14737140.8.10.1689 CrossRefPubMedPubMedCentral

Collignon J, Lousberg L, Schroeder H, Jerusalem G (2016) Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 8:93–107. https://doi.org/10.2147/BCTT.S69488 CrossRef

Diaz D, Vazquez-Polanco AM, Argueta-Donohué J, Stephens CR, Jimenez-Trejo F, Ceballos-Liceaga SE, Mantilla-Beniers N (2018) Incidence of intestinal infectious disease due to protozoa and bacteria in Mexico: analysis of national surveillance records from 2003 to 2012. BioMed Res Int 2018:22. https://doi.org/10.1155/2018/2893012 CrossRef

Dunn OJ (1964) Multiple comparisons using rank sums. Technometrics 6:241–252. https://doi.org/10.1080/00401706.1964.10490181 CrossRef

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389 CrossRefPubMed

Fyke FE 3rd, Seqard JB, Edwards WD, Miller FA Jr, Reeder GS, Schattenberg TT, Schub C, Callahan JA, Tajik AJ (1985) Primary cardiac tumors: experience with 30 consecutive patients since the introduction of two-dimensional echocardiography. J Am Coll Cardiol 5(6):1465–1473. https://doi.org/10.1016/S0735-1097(85)80364-8 CrossRefPubMed

Gallardo-Pérez JC, Rivero-Segura NA, Marín-Hernández A, Moreno-Sánchez R, Rodríguez-Enríquez S (2014) GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroids. Biochim Biophys Acta 1843(6):1043–1053. https://doi.org/10.1016/j.bbamcr.2014.01.013 CrossRefPubMed

Gao L, Chen Q, Zhou X, Fan L (2012) The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol 65(10):872–876. https://doi.org/10.1136/jclinpath-2012-200828 CrossRefPubMed

Goossens N, Nakagawa S, Sun X, Hoshida Y (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4(3):256–269. https://doi.org/10.3978/j.issn.2218-676X.2015.06.04 CrossRefPubMedPubMedCentral

Gošev I, Paić F, Durić Z, Gošev M, Ivčević S, Jakuš FB, Biočina B (2013) Cardiac myxoma the great imitators: comprehensive histopathological and molecular approach. Int J Cardiol 164(1):7–20. https://doi.org/10.1016/j.ijcard.2011.12.052 CrossRefPubMed

Goswami SK, Das DK (2010) Oxygen sensing, cardiac ischemia, HIF-1α and some emerging concepts. Curr Cardiol Rev 6(4):265–273. https://doi.org/10.2174/157340310793566136 CrossRefPubMedPubMedCentral

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657. https://doi.org/10.1200/JCO.2006.06.5664 CrossRefPubMed

Hannah H 3rd, Eisemann G, Hiszcznskyj R, Winsky M, Cohen L (1982) Invasive atrial myxoma: documentation of malignant potential of cardiac myxomas. Am Heart J 104(4 Pt 1):881–883. https://doi.org/10.1016/0002-8703(82)90031-X CrossRefPubMed

Hasegawa T, Nakagawa S, Chino M, Kunihiro T, Ui S, Kimura M (2002) Primary cardiac sarcoma mimicking benign myxoma: a case report. J Cardiol 39(6):321–325PubMed

Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6(2):140–146. https://doi.org/10.1016/j.molonc.2012.01.010 CrossRefPubMedPubMedCentral

Hoffmeier A, Sindermann JR, Scheld HH, Martens S (2014) Cardiac tumors—diagnosis and surgical treatment. Dtsch Arztebl Int 111(12):205–211. https://doi.org/10.3238/arztebl.2014.0205 CrossRefPubMedPubMedCentral

Hong OY, Noh EM, Jang HY, Lee YR, Lee BK, Jung SH, Kim JS, Youn HJ (2017) Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β-catenin signaling pathway. Oncol Lett 14(1):441–446. https://doi.org/10.3892/ol.2017.6108 CrossRefPubMedPubMedCentral

Hou YC, Chang S, Lo HM, Hsiao CH, Lin FY (2001) Recurrent cardiac myxoma with multiple distant metastasis and malignant change. J Formos Med Assoc 100(1):63–65PubMed

Ibarra-Coronado EG, Velazquéz-Moctezuma J, Diaz D, Becerril-Villanueva LE, Pavón L, Morales-Montor J (2015) Sleep deprivation induces changes in immunity in Trichinella spiralis-infected rats. Int J Biol Sci 11(8):901–912. https://doi.org/10.7150/ijbs.11907 CrossRefPubMedPubMedCentral

Isobe S, Murohara T (2015) Editorial: cardiac tumors: histopathological aspects and assessments with cardiac noninvasive imaging. J Cardiol Cases 12:37–38. https://doi.org/10.1016/j.jccase.2015.04.008 CrossRefPubMedPubMedCentral

Iurlaro R, León-Annicchiarico CL, Muñoz-Pinedo C (2014) Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol 542:59–80. https://doi.org/10.1016/B978-0-12-416618-9.00003-0 CrossRefPubMed

Jackson T, Allard MF, Sreenan CM, Doss LK, Bishop SP, Swain JL (1990) The c-myc proto-oncogene regulates cardiac development in transgenic mice. Mol Cell Biol 10(7):3709–3716. https://doi.org/10.1128/MCB.10.7.3709 CrossRefPubMedPubMedCentral

Kalia M (2015) Biomarkers for personalized oncology: recent advances and future challenges. Metabolism 64(3 Suppl 1):S16–S21. https://doi.org/10.1016/j.metabol.2014.10.027 CrossRefPubMed

Kaul P, Paniagua R, Balaji S, Batin P (2013) Large mass in right atrium after CABG—myxoma, adrenal metastasis or in-transit thrombus? Br J Cardiol 20:79. https://doi.org/10.5837/bjc.2013.19 CrossRef

Kaynak K, Beşirli K, Arslan C, Ozgüroğlu M, Oz B (2001) Metastatic cardiac myxoma. Ann Thorac Surg 72(2):623–625. https://doi.org/10.1016/S0003-4975(00)02408-5 CrossRefPubMed

Kidd ME, Shumaker DK, Ridge KM (2014) The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 50(1):1–6. https://doi.org/10.1165/rcmb.2013-0314TR CrossRefPubMedPubMedCentral

Kim SA, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC, Fuchs CS, Wu K, Chan AT, Zhang X, Ogino S, Qian ZR (2016) Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 114(2):199–206. https://doi.org/10.1038/bjc.2015.347 CrossRefPubMedPubMedCentral

Köhrmann A, Kammerer U, Kapp M, Dietl J, Anacker J (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 9:188. https://doi.org/10.1186/1471-2407-9-188 CrossRefPubMedPubMedCentral

Kothari J, Lakhia K, Solanki P, Panchal J, Shah P (2016) Recurrent left atrial myxoma in a young patient: a rare entity. J Clin Diagn Res 10(8):PD05–P7. https://doi.org/10.7860/JCDR/2016/20425.8321 CrossRefPubMedPubMedCentral

Lee VH, Connolly HM, Brown RD Jr (2007) Central nervous system manifestations of cardiac myxoma. Arch Neurol 64(8):1115–1120. https://doi.org/10.1001/archneur.64.8.1115 CrossRefPubMed

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. https://doi.org/10.1172/JCI45014 CrossRefPubMedPubMedCentral

Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 97(8):4262–4266. https://doi.org/10.1073/pnas.060025397 CrossRefPubMed

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr, ASCO (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327. https://doi.org/10.1200/JCO.2006.08.2644 CrossRefPubMed

Loor G, Schumacker PT (2008) Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ 15(4):686–690. https://doi.org/10.1038/cdd.2008.13 CrossRefPubMed

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275PubMed

McCarthy PM, Schaff HV, Winkler HZ, Lieber MM, Carney JA (1989) Deoxyribonucleic acid ploidy pattern of cardiac myxomas. Another predictor of biologically unusual myxomas. J Thorac Cardiovasc Surg 98(6):1083–1086PubMed

Mendoza C, Bernstein E, Ferreira A (2007) Multiple recurrences of nonfamilial cardiac myxomas: a report of two cases. Tex Heart Inst J 34(2):236–239PubMedPubMedCentral

Mohajeri G, Sanei MH, Tabatabaee SA, Hashemi SM, Amjad E, Mohajeri MR, Shemshaki H, Jazi AH, Kolahdouzan M (2012) Micrometastasis in non-small-cell lung cancer: detection and staging. Ann Thorac Med 7(3):149–152. https://doi.org/10.4103/1817-1737.98848 CrossRefPubMedPubMedCentral

Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) EMT: 2016. Cell 166:21–45. https://doi.org/10.1016/j.cell.2016.06.028 CrossRefPubMed

Pacheco-Velázquez SC, Gallardo-Pérez JC, Aguilar-Ponce JL, Villarreal P, Ruiz-Godoy L, Pérez-Sánchez M, Marín-Hernández A, Ruiz-García E, Meneses-García A, Moreno-Sánchez R, Rodríguez-Enríquez S (2014) Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients. Int J Oncol 45(6):2549–2559. https://doi.org/10.3892/ijo.2014.2676 CrossRefPubMed

Pateras IS, Evangelou K, Tsimaratou K, Liontos M, Sakellariou S, Barlogiannis T, Karakitsos P, Papalois A, Kotsinas A, Gorgoulis VG (2012) Detection of herplex simplex virus-1 and -2 in cardiac myxomas. J Biomed Biotechnol 2012:823949. https://doi.org/10.1155/2012/823949 CrossRefPubMedPubMedCentral

Pérez-Andreu J, Parrilla G, Arribas JM, García-Villalba B, Lucas JJ, Garci- Navarro M, Marín F, Gutierrez F, Moreno A (2013) Neurological manifestations of cardiac myxoma: experience in a referral hospital. Neurologia 28(9):529–534. https://doi.org/10.1016/j.nrl.2013.03.006 CrossRefPubMed

Pinede L, Duhaut P, Loire R (2001) Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. Medicine (Baltimore) 80(3):159–172CrossRef

Porcaro AB, de Luyk N, Corsi P, Sebben M, Tafuri A, Tamanini I, Processali T, Cerruto MA, Migliorini F, Brunelli M, Siracusano S, Artibani W (2017) Bilateral lymph node micrometastases and seminal vesicle invasion associated with same clinical predictors in localized prostate cancer. Tumori 103(3):299–306. https://doi.org/10.5301/tj.5000546 CrossRefPubMed

Rathore KS, Hussenbocus S, Stuklis R, Edwards J (2008) Novel strategies for recurrent cardiac myxoma. Ann Thorac Surg 85(6):2125–2126. https://doi.org/10.1016/j.athoracsur.2007.11.080 CrossRefPubMed

Reynen K (1995) Cardiac myxomas. N Engl J Med 333(24):1610–1617. https://doi.org/10.1056/NEJM199512143332407 CrossRefPubMed

Reynen K (1996) Frequency of primary tumors of the heart. Am J Cardiol 77(1):107. https://doi.org/10.1016/S0002-9149(97)89149-7 CrossRefPubMed

Rodríguez-Enríquez S, Pacheco-Velázquez SC, Gallardo-Pérez JC, Marín-Hernández A, Aguilar-Ponce JL, Ruiz-García E, Ruizgodoy-Rivera LM, Meneses-García A, Moreno-Sánchez R (2011) Multi-biomarker pattern for tumor identification and prognosis. J Cell Biochem 112(10):2703–2715. https://doi.org/10.1002/jcb.23224 CrossRefPubMed

Roldán FJ, Vargas-Barrón J, Espinola-Zavaleta N, Keirns C, Romero-Cárdenas A (2000) Recurrent myxoma implanted in the left atrial appendage. Echocardiography 17(2):169–171. https://doi.org/10.1111/j.1540-8175.2000.tb01119.x CrossRefPubMed

Siltanen P, Tuuteri L, Norio R, Tala P, Ahrenberg P, Halonen PI (1976) Atrial myxoma in a family. Am J Cardiol 38(2):252–256. https://doi.org/10.1016/0002-9149(76)90158-2 CrossRefPubMed

Singh S, Singh M, Kovacs D, Benatar D, Khosla S, Singh H (2015) A rare case of an intracardiac lipoma. Int J Surg Case Rep 9:105–108. https://doi.org/10.1016/j.ijscr.2015.02.024 CrossRefPubMedPubMedCentral

Singhal P, Luk A, Rao V, Butany J (2014) Molecular basis of cardiac myxomas. Int J Mol Sci 15(1):1315–1337. https://doi.org/10.3390/ijms15011315 CrossRefPubMedPubMedCentral

Smith M, Chaudhry MA, Lozano P, Humphrey MB (2012) Cardiac myxoma induced paraneoplastic syndromes: a review of the literature. Eur J Intern Med 23(8):669–673. https://doi.org/10.1016/j.ejim.2012.05.015 CrossRefPubMed

Suvarna SK, Royds JA (1996) The nature of the cardiac myxoma. Int J Cardiol 57(3):211–216. https://doi.org/10.1016/S0167-5273(96)02827-6 CrossRefPubMed

Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240(4857):1285–1293. https://doi.org/10.1126/science.3287615 CrossRefPubMed

Tachibana K, Yamasaki D, Ishimoto K, Doi T (2008) The role of PPARs in cancer. PPAR Res 2008:102737, https://doi.org/10.1155/2008/102737 CrossRefPubMedPubMedCentral

Tal R (2012) The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod 87(6):134. https://doi.org/10.1095/biolreprod.112.102723 CrossRefPubMed

Talks K, Turley H, Gatter KC (2000) The expression and distribution of hypoxia inducible factors HIF-1a and HIF-2a in normal human tissues, cancers tumor associated macrophages. Am J Pathol 157(2):411–421. https://doi.org/10.1016/S0002-9440(10)64554-3 CrossRefPubMedPubMedCentral

Tarelo-Saucedo JM, Peñaloza-Guadarrama M, Villela-Caleti J, García-Cruz A, Arizmendi-Monroy DK, Reynada-Torres JL, Martinez-Ramirez L (2016) Surgical results and monitoring of postoperative atrial myxomas. Arch Cardiol Mex 86(1):35–40. https://doi.org/10.1016/j.acmx.2015.09.002 CrossRefPubMed

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142. https://doi.org/10.1038/nrm1835 CrossRefPubMed

Todo T, Usui M, Nagashima K (1992) Cerebral metastasis of malignant cardiac myxoma. Surg Neurol 37(5):374–379. https://doi.org/10.1016/0090-3019(92)90007-A CrossRefPubMed

Tomifuji M, Imanishi Y, Araki K, Yamashita T, Yamamoto S, Kameyama K, Shiotani A (2011) Tumor depth as a predictor of lymph node metastasis of supraglottic and hypopharyngeal cancers. Ann Surg Oncol 18(2):490–496. https://doi.org/10.1245/s10434-010-1219-5 CrossRefPubMed

Vargas-Alarcón G, Vargas-Barrón J, Cruz-Robles D, Pérez-Vielma N, García-Trejo JJ, Aguilar-Gaytán R, Cortés-Hernández P, Vazquez-Ortíz ZY, Romero-Cardenas A (2008) A deletion in the PRKAR1A gene is associated with Carney complex. J Pediatr Endocrinol Metab 21(7):705–709. https://doi.org/10.1515/JPEM.2008.21.7.705 CrossRefPubMed

Vargas-Barron J, Romero-Cardenas A, Villegas M, Keirns C, Gomez-Jaume A, Delong R, Malo-Camacho R (1991) Transthoracic and transesophageal echocardiographic diagnosis of myxomas in the four cardiac cavities. Am Heart J 121(3 Pt 1):931–933. https://doi.org/10.1016/0002-8703(91)90216-5 CrossRefPubMed

Villalpando-Mendoza E, Pérez-Pérez FM, Cortés-Flores AO, Velázquez-Ramírez GA, Fuentes-Orozco C, González-Ojeda A (2006) Frequency of heart tumors and their histopathological correlation. Cir Cir 74(3):183–187PubMed

Wada A, Kanda T, Hayashi R, Imai S, Suzuki T, Murata K (1993) Cardiac myxoma metastasized to the brain: potential role of endogenous interleukin-6. Cardiology 83(3):208–211. https://doi.org/10.1159/000175971 CrossRefPubMed

Wang C, Lisanti MP, Liao DJ (2011) Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 10(1):57–67. https://doi.org/10.4161/cc.10.1.14449 CrossRefPubMedPubMedCentral

Wang S, Cheng Y, Zheng Y, He Z, Chen W, Zhou W, Duan C, Zhang C (2016) PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma. Sci Rep 6:39630. https://doi.org/10.1038/srep39630 CrossRefPubMedPubMedCentral

Wittersheim M, Heydt C, Hoffmann F, Büttner R (2017) KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm? J Pathol Clin Res 3(2):100–104. https://doi.org/10.1002/cjp2.66 CrossRefPubMedPubMedCentral

Wu XY, Liu WT, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G (2016) Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness. Am J Cancer Res 6(9):1935–1948PubMedPubMedCentral

Yadav BS, Chanana P, Jhamb S (2015) Biomarkers in triple negative breast cancer: a review. World J Clin Oncol 6(6):252–263. https://doi.org/10.5306/wjco.v6.i6.252 CrossRefPubMedPubMedCentral

Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59(22):5830–5835PubMed

Titel: Heart myxoma develops oncogenic and metastatic phenotype
verfasst von: Silvia Cecilia Pacheco-Velázquez
Juan Carlos Gallardo-Pérez
Daniel Díaz
Alhelí Adán-Ladrón de Guevara
Diana Xochiquetzal Robledo-Cadena
Emma Saavedra
Luz Ruiz-Godoy
Luis Roberto Jimenez-Hernández
Jesús Vargas-Barrón
José Luis Aguilar-Ponce
Sara Rodríguez-Enríquez
Publikationsdatum: 21.03.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02897-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Heart myxoma develops oncogenic and metastatic phenotype